PharmaFocus Today – Page 59 – media

Net loss after deducting non-recurring items is expected to be 155 million to 220 million yuan in 2024, and revenue and profit of vaccine segment will drop sharply

Wantai Bio announced on January 15 that it expects to achieve net profit attributable to the parent company’s owners of 86 million to 120 million yuan in 2024, a year-on-year decrease of 90.38% to 93.11%; it is expected that the net profit attributable to the parent company’s owners after deducting non-recurring gains and losses in 2024 will be -155 million to -220 million yuan. During the reporting period, the company’s vaccine segment was affected by market adjustments, government centralized procurement and the expansion of the age of the nine-valent HPV vaccine, and sales were not as expected. The revenue and profit of the vaccine segment dropped sharply, resulting in a net loss. At the same time, the company promoted international market sales through multiple methods and channels, and overseas operating income increased by 55% compared with the same period last year. The diagnostics segment benefited from the accelerated advancement of ...
- Source: drugdu
- 134
- January 17, 2025
Full-year sales forecast lowered by $1 billion, what happened to the Chinese factory of the star COVID-19 vaccine company Moderna?

On January 13, American vaccine manufacturer Moderna lowered its 2025 sales forecast by $1 billion to cut costs. The company’s stock price plummeted 17% at the close of the day. Moderna’s latest forecast is that revenue in 2025 will be between $1.5 billion and $2.5 billion, a sharp drop from the $2.5 billion to $3.5 billion forecast in September last year. Moderna said that most of these sales will come from sales of the COVID-19 vaccine and the newly launched respiratory syncytial virus (RSV) vaccine in the second half of 2025. In 2024, the company’s revenue from these two vaccines is about $3 billion. Demand for Moderna’s COVID-19 vaccine is falling rapidly. The company’s COVID-19 vaccine revenue reached $18 billion and $6.7 billion in 2022 and 2023, respectively. Other COVID-19 vaccine manufacturers, Novavax and BioNTech, are also actively seeking transformation. Moderna Chief Financial Officer Jamey Mock said that the company ...
- Source: drugdu
- 136
- January 17, 2025
Bio-Vaccine ETF (562860) rose 2.28%, and three major driving factors promoted the long-term improvement of the vaccine industry

As of 11:25 on January 14, 2025, the CSI Vaccine and Biotechnology Index rose strongly by 2.20%, with constituent stocks BeiGene rising 9.38%, Hualan Vaccine rising 4.95%, Digene Pharmaceuticals rising 4.86%, and Zhixiang Jintai, Dongbao Bio and other stocks following the rise. Bio-Vaccine ETF (562860) rose 2.28%, and the intraday turnover reached 11.6195 million yuan, with a turnover rate of 4.12%. In terms of shares, the latest shares of Bio-Vaccine ETF reached 485 million, a record high in the past month. It is worth noting that the valuation of the CSI Vaccine and Biotechnology Index tracked by the fund is at a historical low, with the latest price-to-book ratio PB being 2.64 times, which is lower than the index’s 89.23% of the time in the past three years, and the valuation cost-effectiveness is outstanding. Data shows that as of December 31, 2024, the top ten weighted stocks of the CSI ...
- Source: drugdu
- 121
- January 17, 2025
Sinovac exclusively won the bid for the Chilean influenza vaccine project. The first batch of vaccines will be sent to Chile tomorrow

On January 14, at the press conference of SINOVAC’s winning bid for the Chilean project, Meng Weining, Vice President and Head of International Business of Sinovac, introduced that on January 10, the trivalent influenza vaccine Anerlife® produced by Beijing Sinovac Biological Products Co., Ltd. under SINOVAC Sinovac exclusively won the bid for the Chilean government’s 2025 annual influenza vaccine global tender. The first batch of vaccines will be sent to Chile on January 15. Meng Weining said that this winning bid means that the influenza vaccines that the Chilean government will provide free of charge to the people of the country in 2025 will all be provided by Sinovac. This is an important breakthrough for Sinovac in the influenza vaccine market in the southern hemisphere, breaking the monopoly of multinational companies in the Chilean market for many years. According to reports, since 2020, Sinovac has supplied a total of 22 ...
- Source: drugdu
- 93
- January 17, 2025
Some people are falling behind in the field of autoimmune TCE

Since 2024, TCE in the field of autoimmune has become completely popular. Overseas pharmaceutical companies continue to bet on this field, and domestic TCE has also become popular, giving birth to two huge transactions in the history of domestic Biotech going overseas, including Tongrun Bio and Merck reaching an acquisition of CD3/CD19 bispecific antibodies, with a down payment of US$700 million, second only to BMS and Baili Tianheng’s cooperation on bispecific ADC; and GSK’s acquisition of Enmu Bio’s CD3/CD19/CD20 trispecific antibody CMG1A46, with a down payment of US$300 million, which is also at a relatively high level. The popularity of autoimmune TCE is a fact, but it is undeniable that this field is also full of unknowns. On January 10, IGM Biosciences, which transformed from tumor to autoimmunity, suffered a blow: the core pipeline CD20xCD3 bispecific antibody IGM-2323 showed a disappointing depth of B cell depletion in the field of ...
- Source: drugdu
- 100
- January 16, 2025
The failure of “snake swallowing elephant” perspective Haier Bio and Shanghai RAAS’s endogenous and exogenous development

After more than a year of twists and turns, the reorganization drama of Haier Bio and Shanghai RAAS ended in termination. On the evening of January 6, 2025, both parties successively issued announcements on the resumption of trading of the company’s stocks. Looking back on this merger and acquisition, the eye-catching thing is “snake swallowing elephant”. On December 20, 2024, Haier Bio and Shanghai RAAS signed the “Absorption Merger Intention Agreement”. Based on the closing stock price of the day, the market value of the two companies was approximately 11.2 billion yuan and 47.9 billion yuan respectively. Regarding the reason for the termination, Haier Bio announced that the transaction structure was relatively complex, and after repeated discussions and consultations among all parties, a specific plan recognized by all parties concerned has not yet been formed. In order to effectively safeguard the interests of listed companies and investors, the two parties ...
- Source: drugdu
- 130
- January 16, 2025
The anti-corruption storm in the pharmaceutical industry will continue to deepen in 2025

On January 8, the Communiqué of the Fourth Plenary Session of the 20th Central Commission for Discipline Inspection of the Communist Party of China was officially released. The document clearly pointed out that as the final year of the 14th Five-Year Plan, the tasks of discipline inspection and supervision in 2025 are particularly important, especially in the fields of medicine and medical insurance funds, where the governance of corruption is clearly listed as a priority. On January 10, Yang Shanhua, chief accountant of China National Pharmaceutical Group Co., Ltd., was investigated. On the same day, the Hainan Provincial Commission for Discipline Inspection and Supervision announced the news that three staff members of the pharmaceutical and health system were investigated. Among them, Xiao Meifang, director of the laboratory department of Hainan Provincial Women and Children’s Medical Center, was suspected of serious violations of discipline and law. This is also the first ...
- Source: drugdu
- 167
- January 16, 2025
Stem cell therapy opens a new era

Recently, NMPA conditionally approved the listing of China’s first mesenchymal stem cell therapy, Amymetose Injection, through the priority review and approval process. Coincidentally, this is also after the FDA approved the marketing of Ryoncil, the first mesenchymal stem cell therapy, on December 18, 2024. The two drugs were approved only 15 days apart, and the indications are both for hormone-refractory acute graft resistance. Host disease. The FDA and NMPA have successively approved the first stem cell drugs, indicating that innovative stem cell drugs have arrived. The tortuous road Looking back at the development and application history of Ryoncil cell drug, we can find that its road to market in the United States was extremely difficult. It took 5 and a half years from the first application in 2019 to the final approval. During this period, I received 2 CRL (application rejection) letters and was in danger of being stranded. It ...
- Source: drugdu
- 237
- January 16, 2025
2025 medical device global exhibition summary

The medical device industry has always been a crucial component of the healthcare sector, with a series of significant offline exhibitions held annually to provide professionals with an opportunity to stay informed about the latest technologies and trends, establish business connections, and promote industry development. In 2025, the medical device field will once again welcome a series of notable exhibitions, offering a rare chance for professionals and medical technology enthusiasts alike. Below is a preliminary compilation of medical device exhibition information for 2025 by Drugdu.com, which we are now sharing with you: January Arab Health Jan. 27-30 Exhibitiors：4200 Dubai February MD&M West Feb. 4-6 Exhibitiors：700 California Medical Expo Feb. 15-17 Exhibitiors：750 Calcutta March Xi ‘an West International Medical Equipment Exhibition Mar. 6-8 Exhibitiors：1300 Xi’an CDMEE Mar. 7-9 Exhibitiors：1200 Chengdu CMEE Mar. 15-17 Exhibitiors：2000 Shandong MEDICAL FAIR INDIA Mar. 27-29 Exhibitiors：419 Greater Noida KIMES Mar. 20-23 Exhibitiors：1200 Seoul April CMEF ...
- Source: drugdu
- 265
- January 15, 2025
2025 Biopharmaceutical global exhibition summary

With the continuous innovation and development in the field of biopharmaceuticals, 2025 will continue to witness a series of industry-specific exhibitions. These exhibitions will provide an excellent opportunity for professionals in the biomedical field to explore the latest scientific research achievements, technological innovations, and industry trends. Whether you are involved in research, pharmaceuticals, biotechnology, or an entrepreneur seeking potential business opportunities, these exhibitions will offer you abundant insights and business prospects. Therefore, in this issue, Drugdu.com has compiled a summary of exhibition information for most of the pharmaceutical industry worldwide in 2025. January DUPHAT Jan. 7-9 Exhibitiors：1100 Dubai Pharmapack Jan. 22-23 Exhibitiors：268 Paris February Asia Pharma Expo Feb. 12-14 Exhibitiors：800 Dacca INTERPHEX Week Osaka Feb. 25-27 Exhibitiors：308 Osaka March Medical Japan Mar. 5-7 Exhibitiors：1400 Osaka Infarma Mar. 25-27 Exhibitiors：430 Madrid April Interphex US Apr. 1-3 Exhibitiors：460 New York CPhI Japan Apr. 9-11 Exhibitiors：712 Tokyo Korea Chem / Korea PHARM & BIO Apr. ...
- Source: drugdu
- 185
- January 15, 2025

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.